FAC ENFERMERIA
Zentrum
ALFONSO
CARVAJAL GARCIA PANDO
Forscher in der Zeit 1986-2015
Publikationen, an denen er mitarbeitet ALFONSO CARVAJAL GARCIA PANDO (11)
2021
-
Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study
Scientific Reports, Vol. 11, Núm. 1
2015
-
Emergency contraceptive pill safety profile. Comparison of the results of a follow-up study to those coming from spontaneous reporting
Pharmacoepidemiology and Drug Safety, Vol. 24, Núm. 1, pp. 93-97
2014
-
A European community pharmacy-based survey to investigate patterns of prescription fraud through identification of falsified prescriptions
European Addiction Research, Vol. 20, Núm. 4, pp. 174-182
-
Knowledge upon the emergency contraceptive pill in Spain
Atencion Farmaceutica, Vol. 16, Núm. 3, pp. 224-228
2013
-
Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study
European Journal of Clinical Pharmacology, Vol. 69, Núm. 3, pp. 559-564
2012
-
Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): Changes in the consumption pattern following the introduction of extended release methylphenidate
Pharmacoepidemiology and Drug Safety, Vol. 21, Núm. 4, pp. 435-441
2011
-
Adverse events associated with pandemic influenza vaccines: Comparison of the results of a follow-up study with those coming from spontaneous reporting
Vaccine, Vol. 29, Núm. 3, pp. 519-522
2010
-
Response to rupatadine and heart rhythm disturbances
Clinical Pharmacology and Therapeutics
2009
-
Heart rhythm disturbances associated with rupatadine: A case series from the Spanish and Portuguese pharmacovigilance systems
Clinical Pharmacology and Therapeutics, Vol. 85, Núm. 5, pp. 481-484
2007
-
Gynaecomastia associated with proton pump inhibitors: A case series from the Spanish pharmacovigilance system
Drug Safety, Vol. 30, Núm. 6, pp. 527-531
2006
-
HMG CoA reductase inhibitors and impotence: Two case series from the Spanish and French drug monitoring systems
Drug Safety, Vol. 29, Núm. 2, pp. 143-149